Commission consults on GMP rules for active substances under EU falsified medicines legislation
This article was originally published in SRA
Executive Summary
The European Commission is seeking feedback on its plan to extend the scope of the medicines Directive 2003/94/EC on good manufacturing practices so that its provisions will also apply to the manufacturing of active substances1,2.